<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564926</url>
  </required_header>
  <id_info>
    <org_study_id>D1690L00067</org_study_id>
    <nct_id>NCT02564926</nct_id>
  </id_info>
  <brief_title>Foxiga Korea Local Phase 4 Study</brief_title>
  <acronym>BEYOND</acronym>
  <official_title>Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month,
      randomised, open-label, parallel-group, multi-centre phase IV study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase IV study.

      Participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1~2 mgqd
      in an open-label manner for 12 months as add-on to metformin 1000 mg.

      Parallel group study design was chosen. In order maintain the practicality of the phase IV
      study, open label design of study drug delivery was chosen. The reading of the DXA scans will
      be conducted by one expert in blinded manner. Glimepiride is the most frequently used SUs in
      Korea and therefore this was chosen as comparator.Dapagliflozin treatment will be associated
      with reduction of total body FM, BW, abdominal VAT and SAT volume compared with glimepiride.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2016</start_date>
  <completion_date type="Actual">January 15, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in HbA1c at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in HbA1c at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>HbA1c &lt;7.0% at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Total Body Weight at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Total Body Weight at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Waist Circumference at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Waist Circumference at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Lean Body Mass at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Lean Body Mass at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Adinopectin at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in Adinopectin at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10mg + Metformin 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with T2DM (Male or female, ≥ 19 and ≤ 75 yrs)

          2. Patients in insufficient glycemic control (HbA1c &gt; 7.5% and &lt; 9.5% in recent 4 weeks)

          3. Patients with an unchanged dose of metformin (≥ 1,000 mg/day) for &gt; 8 weeks prior to
             randomization

          4. Written informed consent

          5. WOCBP must take precautions to avoid pregnancy throughout the study and for 4 weeks
             after intake of the last dose.

               -  WOCBP must have a negative urine pregnancy test at screening visit WOCBP include
                  any female who has experienced menarche and who has not undergone successful
                  surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral
                  oophorectomy) or is not postmenopausal.

               -  WOCBP must be willing to use a medically accepted method of contraception that is
                  considered reliable in the judgment of the Investigator.

        Exclusion Criteria:

          1. Type 1 diabetes or history of diabetic ketoacidosis

          2. Pregnant or breast-feeding patients

          3. eGFR &lt; 60 mL/min/1.73 m2 (MDRD) on visit 1.

          4. Indication of active liver disease (AST/ALT/total bilirubin &gt; 3 X upper limits of
             normal) on visit 1.

          5. Acute coronary syndrome, stroke or TIA within 3 months prior to randomization

          6. Bariatric surgery within 2 years; treatment of anti-obesity drugs 3 months prior to
             randomization; any treatment leading to unstable body weight. (Unstable body weight is
             considered reliable in the judgment of the Investigator.)

          7. History of bladder cancer or history of radiation therapy to the lower abdomen or
             pelvis at any time

          8. History of any other malignancy within 5 years (with the exception of successfully
             treated non-melanoma skin cancers)

          9. History of alcohol or drug abuse judged by physician within 3 months prior to
             randomization

         10. Concomitant participation in any other clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ansan-si</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changwon-si</city>
        <zip>51353</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon-si</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uijeongbu-si</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3942&amp;filename=D1690l00067_CSP_Redacted.pdf</url>
    <description>D1690l00067_CSP_Redacted</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3942&amp;filename=D1690l00067_SAP_Redacted.pdf</url>
    <description>D1690l00067_SAP_Redacted</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02564926/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02564926/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 05 January 2016 Last patient last visit: 15 January 2018</recruitment_details>
      <pre_assignment_details>178 patients provided informed consent. 121 patients received study treatment and were included in the SAF population. 112 patients received study treatment and had at least one post-baseline primary efficacy assessment and were included in the FAS population (56 patients in each treatment group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10mg + Metformin 1000mg</description>
        </group>
        <group group_id="P2">
          <title>Glimepiride</title>
          <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10mg + Metformin 1000mg</description>
        </group>
        <group group_id="B2">
          <title>Glimepiride</title>
          <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="9.09"/>
                    <measurement group_id="B2" value="55.7" spread="10.24"/>
                    <measurement group_id="B3" value="55.2" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan</title>
        <description>Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan</title>
          <description>Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1485.69" lower_limit="-2025.543" upper_limit="-945.844"/>
                    <measurement group_id="O2" value="1096.34" lower_limit="556.489" upper_limit="1636.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (kg)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.346</ci_lower_limit>
            <ci_upper_limit>-1.819</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in HbA1c at Week 52</title>
        <description>Adjusted Mean Change in HbA1c at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in HbA1c at Week 52</title>
          <description>Adjusted Mean Change in HbA1c at Week 52</description>
          <units>percentages</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.259" upper_limit="-0.745"/>
                    <measurement group_id="O2" value="-0.54" lower_limit="-0.802" upper_limit="-0.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (%)</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.821</ci_lower_limit>
            <ci_upper_limit>-0.094</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c &lt;7.0% at Week 52</title>
        <description>HbA1c &lt;7.0% at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c &lt;7.0% at Week 52</title>
          <description>HbA1c &lt;7.0% at Week 52</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Count of participants that achieved the response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.343</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>3.113</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</title>
        <description>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</title>
          <description>Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52</description>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.94" lower_limit="-40.084" upper_limit="-21.800"/>
                    <measurement group_id="O2" value="-12.70" lower_limit="-21.786" upper_limit="-3.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (mg/dL)</param_type>
            <param_value>-18.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.140</ci_lower_limit>
            <ci_upper_limit>-5.351</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Total Body Weight at Week 52</title>
        <description>Adjusted Mean Change in Total Body Weight at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Total Body Weight at Week 52</title>
          <description>Adjusted Mean Change in Total Body Weight at Week 52</description>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-3.104" upper_limit="-1.664"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.545" upper_limit="1.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (kg)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.667</ci_lower_limit>
            <ci_upper_limit>-2.631</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Waist Circumference at Week 52</title>
        <description>Adjusted Mean Change in Waist Circumference at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Waist Circumference at Week 52</title>
          <description>Adjusted Mean Change in Waist Circumference at Week 52</description>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" lower_limit="-3.480" upper_limit="-1.253"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-1.271" upper_limit="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (cm)</param_type>
            <param_value>-2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.785</ci_lower_limit>
            <ci_upper_limit>-0.635</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</title>
        <description>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</title>
          <description>Adjusted Mean Change in Body Mass Index (BMI) at Week 52</description>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.172" upper_limit="-0.640"/>
                    <measurement group_id="O2" value="0.46" lower_limit="0.194" upper_limit="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (kg/m2)</param_type>
            <param_value>-1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.742</ci_lower_limit>
            <ci_upper_limit>-0.990</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</title>
        <description>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</title>
          <description>Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" lower_limit="-5.123" upper_limit="0.766"/>
                    <measurement group_id="O2" value="4.63" lower_limit="1.682" upper_limit="7.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (mmHg)</param_type>
            <param_value>-6.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.969</ci_lower_limit>
            <ci_upper_limit>-2.641</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</title>
        <description>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</title>
          <description>Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-2.523" upper_limit="2.023"/>
                    <measurement group_id="O2" value="2.36" lower_limit="0.092" upper_limit="4.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (mmHg)</param_type>
            <param_value>-2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.829</ci_lower_limit>
            <ci_upper_limit>0.600</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52</title>
        <description>Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52</title>
          <description>Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52</description>
          <units>cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.06" lower_limit="-23.806" upper_limit="-8.317"/>
                    <measurement group_id="O2" value="1.48" lower_limit="-6.407" upper_limit="9.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (cm2)</param_type>
            <param_value>-17.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.603</ci_lower_limit>
            <ci_upper_limit>-6.489</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52</title>
        <description>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52</title>
          <description>Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52</description>
          <units>cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.41" lower_limit="-11.804" upper_limit="0.994"/>
                    <measurement group_id="O2" value="12.98" lower_limit="6.462" upper_limit="19.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (cm2)</param_type>
            <param_value>-18.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.561</ci_lower_limit>
            <ci_upper_limit>-9.218</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</title>
        <description>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</title>
          <description>Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52</description>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.115" upper_limit="0.017"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.084" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.127</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Lean Body Mass at Week 52</title>
        <description>Adjusted Mean Change in Lean Body Mass at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Lean Body Mass at Week 52</title>
          <description>Adjusted Mean Change in Lean Body Mass at Week 52</description>
          <units>Kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.608" upper_limit="-0.570"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.329" upper_limit="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.992</ci_lower_limit>
            <ci_upper_limit>-0.540</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Adinopectin at Week 52</title>
        <description>Adjusted Mean Change in Adinopectin at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Adinopectin at Week 52</title>
          <description>Adjusted Mean Change in Adinopectin at Week 52</description>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1746.66" lower_limit="1296.144" upper_limit="2197.181"/>
                    <measurement group_id="O2" value="1088.95" lower_limit="638.431" upper_limit="1539.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (ng/mL)</param_type>
            <param_value>657.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.325</ci_lower_limit>
            <ci_upper_limit>1297.101</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</title>
        <description>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</title>
          <description>Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52</description>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" lower_limit="-1.030" upper_limit="0.014"/>
                    <measurement group_id="O2" value="-0.39" lower_limit="-0.914" upper_limit="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.756</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (mg/L)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.858</ci_lower_limit>
            <ci_upper_limit>0.625</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan</title>
        <description>Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 10mg + Metformin 1000mg</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan</title>
          <description>Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment</description>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" lower_limit="-1.821" upper_limit="-0.604"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.123" upper_limit="1.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference (%)</param_type>
            <param_value>-1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.807</ci_lower_limit>
            <ci_upper_limit>-1.082</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 10mg + Metformin 1000mg</description>
        </group>
        <group group_id="E2">
          <title>Glimepiride</title>
          <description>Glimepiriide 1-2mg + Metformin 1000mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution and PI shall provide the Company with copies of any materials relating to the Study that either intends to publish (or submit for publication) or make any presentations relating to, at least 30 days in advance of publication
At the request of the Company, the Institution and PI shall withhold publication for a period of 90 days from the date on which the Company receives the material.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>EunYoung Kim / Local Study Specialist</name_or_title>
      <organization>Astrazeneca, Korea</organization>
      <phone>82 2 2188 0946 ext 0946</phone>
      <email>EunYoung.Kim@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

